

AMENDMENTS TO THE CLAIMS

1. (Currently amended) An agonist antibody ~~which~~ that specifically binds to a TACI receptor ~~comprising amino acids 2 to 166 of SEQ ID NO: 3~~ and inhibits B cell proliferation.

2. (Original) The antibody of claim 1, wherein the antibody does not bind BCMA receptor.

3. (Original) The antibody of claim 1, wherein the antibody is a monoclonal antibody.

4. (Currently amended) The monoclonal antibody of claim 3, wherein said monoclonal antibody comprises ~~the 1G10.1.5 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-4297; the 5B6.3.10 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-4298, or the variable domain of the 6D11.3.1 antibody secreted~~ produced by the hybridoma deposited with ATCC as accession number PTA-4299 or the variable domain of the 7B6.15.11 antibody produced by the hybridoma deposited with ATCC as accession number PTA-5000.

5. (Currently amended) ~~A monoclonal antibody which~~ The monoclonal antibody of claim 3, wherein said antibody binds to the same epitope as the epitope to which the 1G10.1.5 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-4297 binds; the 5B6.3.10 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-4298 binds; or the 6D11.3.1 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-4299 binds or binds to the same epitope to which the 7B6.15.11 antibody produced by the hybridoma deposited with ATCC as accession number PTA-5000 binds.

6-9. (Cancelled)

10. (Withdrawn) The hybridoma cell line which produces monoclonal antibody 6D11.3.1 and deposited with ATCC as accession number PTA-4299.

11. (Withdrawn) The monoclonal antibody 6D11.3.1 secreted by the hybridoma deposited with ATCC as accession number PTA-4299.

12-13. (Cancelled)

14. (Currently amended) ~~An isolated anti-TACI receptor monoclonal antibody, comprising an antibody which binds to TACI receptor comprising amino acids 2 to 166 of SEQ ID NO: 3 and~~ The monoclonal antibody of claim 3, wherein the antibody competitively inhibits binding of the 6D11.3.1 monoclonal antibody produced by the hybridoma deposited as ATCC PTA-4299 or the 7B6.15.11 monoclonal antibody produced by the hybridoma deposited as ATCC PTA-5000 to said TACI receptor.

15-22. (Cancelled)

23. (Currently amended) ~~An antibody that specifically binds to a TACI receptor and inhibits B-cell proliferation and~~ The antibody of claim 1, wherein the antibody does not inhibit BLyS binding to TACI receptor.

24. (Cancelled)

25. (Currently amended) The antibody according to claim ~~4-5~~, wherein the antibody is the 7B6.15.11 antibody produced by the hybridoma cell line deposited with ATCC as 7B6.15.11 (Accession No. PTA-5000) on February 11, 2003.

26-27. (Cancelled)

28. (Currently amended) A hybridoma cell line which produces monoclonal antibody the ~~7B6~~ 7B6.15.11 ~~monoclonal antibody~~ and was deposited with ATCC as 7B6.15.11 (Accession No. PTA-5000).

29-30. (Cancelled)

31. (Currently amended) ~~A monoclonal antibody which specifically binds to TACI polypeptide and~~ The antibody of claim 1, wherein the antibody comprises a sequence derived from the variable domain of the 7B6.15.11 an antibody produced by the hybridoma deposited with ATCC as accession number PTA-5000 or a sequence derived from the variable domain of the 6D11.3.1 antibody produced by the hybridoma deposited with ATCC as accession number PTA-4299.

32-36. (Cancelled)

37. (Currently amended) The antibody of ~~antibody of any one of claims 23, 26, 30 and 31~~ claim 1, which is glycosylated.

38. (Currently amended) The antibody of claim 1, which is unglycosylated.

39-45. (Cancelled)

46. (Currently amended) The antibody ~~according to~~ of claim 45 ~~1~~, wherein the antibody inhibits BlyS BLyS binding to said TACI receptor.

47. (Cancelled)

48. (Cancelled)

49. (Currently amended) The antibody ~~according to any one of claims 45-47~~ of claim 1, wherein the antibody is a chimeric antibody ~~or a humanized antibody~~.

50. (Currently amended) The antibody ~~according to any one of claims 45-47~~ of claim 1, wherein the antibody is linked to one or more non-proteinaceous polymers selected from the group consisting of polyethylene glycol, polypropylene glycol and polyoxyalkylene.

51. (Currently amended) The antibody ~~according to any one of claims 45-47~~ of claim 1, wherein the antibody is linked to a cytotoxic agent or enzyme.

52. (Currently amended) The antibody ~~according to any one of claims 45-47~~ of claim 1, wherein the antibody is linked to a radioisotope, fluorescent compound or chemiluminescent compound.

53. (New) The antibody of claim 1, wherein the antibody is a humanized antibody

54. (New) The antibody of claim 1, wherein the antibody is an antibody fragment.

55. (New) The antibody of claim 1, wherein the TACI receptor comprises amino acids 2 to 166 of SEQ ID NO: 3.

56. (New) The antibody of claim 23 or 31, wherein the antibody is a humanized antibody.